Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4082731 | 1.00 | SLC7A5 (0.32) | SLC7A5TP53 | |
| SCHEMBL4089087 | 1.00 | SLC7A5 (0.32) | SLC7A5TP53 | |
| SCHEMBL79569 | 0.85 | TP53 (0.35) | SLC7A5TP53 | |
| SCHEMBL10308340 | 0.85 | TP53 (0.35) | TP53 | |
| Hydrogen Peroxide SCHEMBL8161423 | 0.81 | TP53 (0.41) | SLC7A5TP53 | |
| Methyl Alcohol SCHEMBL8058445 | 0.81 | TP53 (0.33) | SLC7A5TP53 | |
| Acetone SCHEMBL5322639 | 0.79 | LMNA (0.43) | SLC7A5TP53 | |
| Formaldehyde SCHEMBL79597 | 0.79 | SLC7A5 (0.32) | SLC7A5TP53 | |
| Isopropyl Alcohol SCHEMBL1325429 | 0.79 | ALDH1A1 (0.43) | SLC7A5TP53 | |
| SCHEMBL11337912 | 0.78 | TP53 (0.33) | TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295201-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20170101431-A1 | NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF CANCER | IDENIX PHARMACEUTICALS LLC (US) | 2017-04-13 | — | — | US | disclosed |
| US-9580467-B2 | Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof | E. R. SQUIBB & SONS, L.L.C. (US) | 2017-02-28 | — | — | US | disclosed |
| US-20160060294-A1 | ANTIPROLIFERATIVE COMPOUNDS, CONJUGATES THEREOF, METHODS THEREFOR, AND USES THEREOF | E. R. SQUIBB & SONS, L.L.C. | 2016-03-03 | — | — | US | disclosed |
| US-9226974-B2 | Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof | E. R. SQUIBB & SONS, L.L.C. (US) | 2016-01-05 | — | — | US | disclosed |
| US-8802632-B2 | Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof | MEDAREX, L.L.C. (US) | 2014-08-12 | — | — | US | disclosed |
| US-8772543-B2 | Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof | MEDAREX, L.L.C. (US) | 2014-07-08 | — | — | US | disclosed |
| US-8772542-B2 | Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof | MEDAREX, L.L.C. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20130204033-A1 | ANTIPROLIFERATIVE COMPOUNDS, CONJUGATES THEREOF, METHODS THEREFOR, AND USES THEREOF | MEDAREX, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130197259-A1 | ANTIPROLIFERATIVE COMPOUNDS, CONJUGATES THEREOF, METHODS THEREFOR, AND USES THEREOF | MEDAREX, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130189256-A1 | ANTIPROLIFERATIVE COMPOUNDS, CONJUGATES THEREOF, METHODS THEREFOR, AND USES THEREOF | MEDAREX, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-8394922-B2 | Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof | MEDAREX, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-20120115951-A1 | PROTECTIVE ACTION OF SEROFENDIC ACID ON CARDIAC MUSCLE | Eisai R & D Managment Co., Ltd (JP) | 2012-05-10 | — | — | US | disclosed |
| US-20110027274-A1 | ANTIPROLIFERATIVE COMPOUNDS, CONJUGATES THEREOF, METHODS THEREFOR, AND USES THEREOF | MEDAREX, INC. (US) | 2011-02-03 | — | — | US | disclosed |
| US-7211589-B2 | Atisane compounds and use thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295201-A1 | ANTIVIRAL COMPOUNDS | MAVS, HAVCR2, ZC3HAV1 | SLC7A5 3150/4885TP53 3535/4885 |
| US-20170101431-A1 | NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF CANCER | TYMP, NSUN2, PNP | SLC7A5 2330/4885TP53 87/4885 |
| US-20160060294-A1 | ANTIPROLIFERATIVE COMPOUNDS, CONJUGATES THEREOF, METHODS THEREFOR, AND USES THEREOF | WEE1, NGLY1, CD81 | SLC7A5 1658/4885TP53 25/4885 |
| US-20110027274-A1 | ANTIPROLIFERATIVE COMPOUNDS, CONJUGATES THEREOF, METHODS THEREFOR, AND USES THEREOF | WEE1, NGLY1, CD81 | SLC7A5 1658/4885TP53 25/4885 |
| US-20130189256-A1 | ANTIPROLIFERATIVE COMPOUNDS, CONJUGATES THEREOF, METHODS THEREFOR, AND USES THEREOF | WEE1, NGLY1, CD81 | SLC7A5 1658/4885TP53 25/4885 |
| US-20120115951-A1 | PROTECTIVE ACTION OF SEROFENDIC ACID ON CARDIAC MUSCLE | TNNC1, TNNT2, TNNI3 | SLC7A5 2010/4885TP53 4716/4885 |
| US-20130197259-A1 | ANTIPROLIFERATIVE COMPOUNDS, CONJUGATES THEREOF, METHODS THEREFOR, AND USES THEREOF | WEE1, NGLY1, CD81 | SLC7A5 1658/4885TP53 25/4885 |
| US-20130204033-A1 | ANTIPROLIFERATIVE COMPOUNDS, CONJUGATES THEREOF, METHODS THEREFOR, AND USES THEREOF | WEE1, NGLY1, CD81 | SLC7A5 1658/4885TP53 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.